Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that
causes significant disability and healthcare burden. The treatment of MS has evolved over …

Ocrelizumab (Ocrevus®) is an intravenously administered, humanized anti-CD20
monoclonal antibody approved for the treatment of adults with relapsing forms of multiple …

Objective This study was undertaken to assess the impact of immunosuppressive and
immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID‐19) in …

Secondary hypogammaglobulinemia (SHG) is characterized by reduced immunoglobulin
levels due to acquired causes of decreased antibody production or increased antibody loss …

Although most autoimmune diseases are considered to be CD4 T cell-or antibody-mediated,
many respond to CD20-depleting antibodies that have limited influence on CD4 and plasma …

Multiple sclerosis (MS) is a chronic inflammatory, demyelinating and neurodegenerative
disease affecting the central nervous system (CNS), often characterized by the accumulation …

Objective To evaluate the clinical consequences of extended interval dosing (EID) of
ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) during the coronavirus disease …

Currently, there are four monoclonal antibodies (mAbs) that target the cluster of
differentiation (CD) 20 receptor available to treat multiple sclerosis (MS): rituximab …

Background: Ofatumumab is approved for the treatment of relapsing multiple sclerosis
(RMS). Ongoing safety reporting is crucial to understand its long-term benefit–risk profile …

COVID-19 vaccination is recommended for multiple sclerosis patients. Disease-modifying
therapies can influence the safety and efficacy of COVID-19 vaccines. RNA, DNA, protein …